Listen: JPM21: Déjà vu in Alzheimer’s research, debatable valuations in biotech, and OWS’s legacy
Is Alzheimer’s research stuck in a rut? Can genome editing live up to the hype? And how will we remember Operation Warp Speed? We discuss all that and more this …
Read More